AlgoNomics granted patent rights for Epibase
Immunogenicity screening tool for protein therapeutics granted a European patent.
Advertisement
AlgoNomics NV announced that notice of grant has been received from the European Patent Office for a key patent covering its Epibase® technology. Epibase® is applied for the immunogenicity screening and optimization of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines. The patent relates to AlgoNomics' method to identify T-cell epitopes through the physicochemical interactions of the epitopes with their HLA Class-I and Class-II receptors.
Philippe Stas, COO of AlgoNomics: "We provide the state of the art in modeling of proteins, and this patent confirms our pioneering role in the field of immunogenicity screening and epitope identification."
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous